期刊文献+

角膜缘血管选择性电凝联合羊膜移植治疗角膜新生血管

Treating corneal transplantation by selective electric coagulating blood vessel of corneal limbus associated with amniotic membrane grafting
下载PDF
导出
摘要 目的评价角膜缘血管选择性电凝联合羊膜移植治疗角膜新生血管的临床疗效。方法对感染、外伤等原因导致的角膜新生血管62眼行角膜缘血管选择性电凝联合羊膜移植术。所有患者术后随访12个月。结果术后5d视力提高1行以上者50眼,术后视力未见变化12眼。原有新生血管数量减少,角膜水肿混浊程度减轻,角膜炎症、角膜溃疡得到改善,角膜透明性有所提高。术后12个月,新生血管完全消失24眼,占38.71%;复发22眼,占35.50%.结论角膜缘血管选择性电凝联合羊膜移植治疗角膜新生血管有效,无明显副作用,能减轻急性期的炎症反应,为角膜复明手术提供良好的条件,但远期效果及复发问题有待进一步观察。 Objective To evaluate the curative effects of selective electric coagulating blood vessel of corneal limbus associated with amniotic membrane grafting in treatment of corneal neovascularization.Methods Sixty-two eyes with corneal neovascularization caused by infection or injury were treated by selective electric coagulating associated with amniotic membrane grafting. All the patients were followed up of 12 months after operation. Results At the 5th day operation, visual acuity was improved of up to one line in 50 eyes,unchanged in 12 eyes. The number of neovaseularization was decreaced and the degree of corneal swollen and dimness was lessened. The inflammation and ulcer of cornea were less serious and the corneal transparency was more or less improved. APter operation, the neovaseularization was disappeared completely in 12 months in 24 eyes, the effective rate was 38. 71%. The rate of recurrence was 35.5% (22 eyes) in 12 months after operation. Conclusion It is effective and has no apparent side effects to treat corneal neovaseularization by selective electric coagulating blood vessel of corneal limbus associated with amniotic membrane grafting, which can lessen the inflammatory reaction in acute period. Thus it is profitable to the operation for corneal recuperation. However, long-term effect and recurrence of corneal neovascularization still need to be studied.
出处 《眼科新进展》 CAS 2007年第1期47-49,共3页 Recent Advances in Ophthalmology
关键词 角膜新生血管 电凝 羊膜移植 corneal neovascularization electric coagulation amniotic membrane grafting
  • 相关文献

参考文献9

二级参考文献40

  • 1[4]Pournars CJ,Miller JW,Gragoudas ES,et al.Systemic hyperoxia decreases vascular endothelial growth factor gene expression in ischemic primate retina[J].Arch Ophthalmol 1997;115:1553.
  • 2[5]D′Amato RJ,Loughnan MS,Flynn E,et al.Thalidomide is an inhibitor of angiogenesis[J].Proc Ncad Sci USA 1994;91:4082.
  • 3[6]Philips GD,Stone AM,Jones BD,Schultz JC.Vascular endothelial growth factor stimulates direct angiogenesis in the rabbit cornea[J].In Vivo 1994;8: 961.
  • 4[7]Kawai K,Yamada M,Haa Y,et al.The role of cyclooxgenase-2 induced by chemical cautery in corneal angiogenesis in the rat[J].Invest Ophthalmol Vis Sci 1998;39(4):S743.
  • 5[8]Gaudry M,Bregerie O,Andrieu V,et al.Intracellular pool of vascular endothelial growth factor in human neutrophils[J].J Blood 1997;90:4153.
  • 6[9]Dana MR,Zhu SN,Yamada J.Topical modulation of interleukin-1 activity in corneal neovascularization[J].Cornea 1998;17(4):403.
  • 7[1]Folkman J,Shing Y.Angiogenesis[J].J Biol Chem 1992;267:10931.
  • 8[2]Myoken Y,Kayda Y,Okamoto T,et al.Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites[J].Proc Natl Acad Sci USA 1991;88:5819.
  • 9[3]Folkman J,Haudenschild C.Angiogenesis in vitro[J].Nature 1980;288:551.
  • 10Streilein JW, Bradley D, Sano Y, et al. Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas. Invest Ophthalmol Vis Sci, 1996, 37 (2): 413-424.

共引文献465

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部